LYEL
$20.14
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtage...
Recent News
Lyell Immunopharma: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. AP) — Lyell Immunopharma Inc. LYEL) on Thursday reported a loss of $140.7 million in its fourth quarter.
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs
Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain
Key Insights Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable...